Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.

[1]  F. Bessone,et al.  Molecular pathways of nonalcoholic fatty liver disease development and progression , 2018, Cellular and Molecular Life Sciences.

[2]  Yuan Yuan,et al.  The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα , 2018, Bioscience reports.

[3]  B. Ren,et al.  Hepatoprotective Effect of Loquat Leaf Flavonoids in PM2.5-Induced Non-Alcoholic Fatty Liver Disease via Regulation of IRs-1/Akt and CYP2E1/JNK Pathways , 2018, International journal of molecular sciences.

[4]  Xuemei Zhang,et al.  Protective Effects of Taraxasterol against Ethanol-Induced Liver Injury by Regulating CYP2E1/Nrf2/HO-1 and NF-κB Signaling Pathways in Mice , 2018, Oxidative medicine and cellular longevity.

[5]  Guangji Wang,et al.  Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Kee-Hong Kim,et al.  1,25-Dihydroxyvitamin D regulates lipid metabolism and glucose utilization in differentiated 3T3-L1 adipocytes. , 2018, Nutrition research.

[7]  Qinhe Yang,et al.  Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway , 2018, Evidence-based complementary and alternative medicine : eCAM.

[8]  X. Yao,et al.  Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats. , 2018, Journal of ethnopharmacology.

[9]  Ting Li,et al.  3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways , 2018, Acta Pharmacologica Sinica.

[10]  T. Zeng,et al.  Impairment of Akt activity by CYP2E1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver , 2017, Redox biology.

[11]  M. Yoneda,et al.  Current and future pharmacological therapies for NAFLD/NASH , 2017, Journal of Gastroenterology.

[12]  Z. Younossi,et al.  Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. , 2017, Clinics in liver disease.

[13]  Bang-Mao Wang,et al.  Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. , 2017, Experimental and therapeutic medicine.

[14]  Yu-ying Liu,et al.  Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. , 2017, Journal of ethnopharmacology.

[15]  Feng Zhu,et al.  Remote ischemic preconditioning protects liver ischemia-reperfusion injury by regulating eNOS-NO pathway and liver microRNA expressions in fatty liver rats. , 2017, Hepatobiliary & pancreatic diseases international : HBPD INT.

[16]  Z. Hong,et al.  Pien Tze Huang Gan Bao attenuates carbon tetrachloride-induced hepatocyte apoptosis in rats, associated with suppression of p53 activation and oxidative stress , 2017, Molecular medicine reports.

[17]  D. Cui,et al.  The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice , 2017, BMC Immunology.

[18]  Y. Rotman,et al.  Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease , 2016, Gut.

[19]  Yan Yu,et al.  Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα. , 2016, Nutrition research.

[20]  Q. Anstee,et al.  Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. , 2016, Annual review of pathology.

[21]  W. Wahli,et al.  Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD , 2016, Gut.

[22]  Hui Wang,et al.  Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress. , 2015, Journal of ethnopharmacology.

[23]  N. Chalasani,et al.  Pharmacotherapy for Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.

[24]  Z. C. Thent,et al.  Fructose-Drinking Water Induced Nonalcoholic Fatty Liver Disease and Ultrastructural Alteration of Hepatocyte Mitochondria in Male Wistar Rat , 2015, BioMed research international.

[25]  Shaoping Ji,et al.  Exogenous hydrogen sulfide mitigates the fatty liver in obese mice through improving lipid metabolism and antioxidant potential , 2015, Medical gas research.

[26]  Sonia J. Park,et al.  LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver. , 2014, Biochemical pharmacology.

[27]  A. Nanji,et al.  Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways , 2014, European Journal of Nutrition.

[28]  C. Anuradha,et al.  Nitric oxide mediates the insulin sensitizing effects of β-sitosterol in high fat diet-fed rats. , 2013, Nitric oxide : biology and chemistry.

[29]  Ying Han,et al.  [Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease]. , 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[30]  Xiao-rong Zhan,et al.  Impaired PI3K/Akt signal pathway and hepatocellular injury in high-fat fed rats. , 2010, World journal of gastroenterology.

[31]  T. Willson,et al.  Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men , 2008, Diabetes.

[32]  Y. Huang,et al.  High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. , 2006, Life sciences.

[33]  N. Fujii,et al.  p38γ MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle , 2004 .

[34]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.